• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Zoledronic acid may increase bone density in frail elderly women

byShayna BejaimalandJames Jiang
April 14, 2015
in Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A single dose of zoledronic acid improved bone mineral density over 2 years in frail elderly women.

2. Rates of fracture or mortality did not differ significantly between zoledronic acid treatment and placebo groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Although as many as 85% of frail elderly adults living in long-term homes have osteoporosis, the current use of bisphosphonate therapy is low. Previous randomized controlled trials studying osteoporosis have not examined the efficacy of bisphosphonates in this population, and given physiological differences in the elderly, the efficacy and safety of bisphosphonates may be vastly different. This study aimed to determine the efficacy and safety of zoledronic acid to treat osteoporosis in frail elderly women living in long-term care facilities.

In this randomized controlled trial, a single dose of zoledronic acid improved bone mineral density in the population over 2 years. However, there was no significant decrease in rates of fracture or mortality across groups. Strengths of this study include studying this outcome in a novel yet important patient population. Limitations include the specific patient population selected, which may limit the generalizability of the results. Moreover, this study was not sufficiently powered to determine zoledronic acid’s effect on fracture rates, so further study regarding this question is warranted.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis

RELATED REPORTS

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures

Bisphosphonate use and risk of atypical femur fractures

In-Depth [randomized controlled trial]: This double-blind, randomized controlled trial was performed in Pittsburgh, Pennsylvania from December 2007 to March 2012, and randomized a total of 181 frail elderly women to either a single dose of zoledronic acid 5 mg with vitamin D and calcium, or placebo (i.e., vitamin D and calcium alone). The primary outcome was hip and spine bone mineral density at 12 and 24 months. Secondary outcomes included rate of fracture and mortality. Data was analyzed using linear mixed model regression, χ2 and Fisher exact tests.

After randomization, the treatment group included more women with frailty, falls history, diabetes and anticonvulsant use. Women in the treatment group had a greater mean (standard error, SE) bone mineral density changes in the hip and spine at 24 months as compared to the placebo group: 2.6% (0.6%) vs. -1.5% (0.7%); p < 0.001 and 4.5% (0.8%) vs. 0.7% (0.5%); p < 0.001. Similar differences were also seen at the 12-month mark. Differences in fracture rates were not significant between groups – 20% for the treatment group and 16% for the placebo group (OR 1.30; 95%CI 0.61-2.78). Mortality rates also did not differ significantly across groups (OR 1.24; 95% CI 0.54-2.86).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bisphosphonatesosteoporosis
Previous Post

Study participants prefer less demanding consent

Next Post

Cutaneous microneedle flu vaccination reduces skin irritation and improves effectiveness [PreClinical]

RelatedReports

Romosozumab significantly increases bone mineral density in postmenopausal women
Chronic Disease

Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk

January 30, 2023
Eczema more prevalent among older adults than previously thought
Chronic Disease

Association of potent topical corticosteroids and the risk of osteoporosis and major osteoporotic fractures

January 27, 2021
Bisphosphonate use and risk of atypical femur fractures
Chronic Disease

Bisphosphonate use and risk of atypical femur fractures

August 26, 2020
Vitamin D supplementation amongst post-menopausal women did not improve functional outcomes
Chronic Disease

Delayed denosumab doses associated with increased the risk of vertebral fractures

July 30, 2020
Next Post
Vaccines for predicted influenza strains may provide wide protection [PreClinical]

Cutaneous microneedle flu vaccination reduces skin irritation and improves effectiveness [PreClinical]

Nonleg venous thromboses associated with PE, longer ICU stay

Patient screening and monitoring improve dabigatran (Pradaxa) adherence

Weight loss surgery may reduce risk of developing type 2 diabetes

Gestational diabetes linked to autism spectrum disorder

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Exhaled volatile organic compounds predict bronchopulmonary dysplasia in preterm infants
  • Wellness Check: Mental Health
  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options